Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

15 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  May 17, 2017

Mid-Morning Market Update: Markets Open Lower; Target Tops Q1 Expectations

Benzinga.com  May 17, 2017

Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies

GlobeNewswire May 16, 2017

Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference

GlobeNewswire May 15, 2017

Syndax Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Clinical and Business Update

GlobeNewswire May 8, 2017

Investor Network: Syndax Pharmaceuticals Inc. to Host Earnings Call

Accesswire May 8, 2017

Syndax to Announce First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 8, 2017

GlobeNewswire May 1, 2017

Syndax Announces Expansion of Immuno-Oncology Collaboration Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Colorectal Cancer

GlobeNewswire April 27, 2017

Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting

GlobeNewswire April 20, 2017

Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors

GlobeNewswire April 4, 2017

Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

GlobeNewswire March 29, 2017

Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

GlobeNewswire March 2, 2017

Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

GlobeNewswire February 27, 2017

Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017

GlobeNewswire February 16, 2017

Syndax Appoints Richard P. Shea as Chief Financial Officer

GlobeNewswire February 9, 2017

Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

GlobeNewswire January 31, 2017

Syndax's CEO Presents 3 Immediate Objectives, Possible Partnerships, Drug Pricing And More

Benzinga.com  January 20, 2017

Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

GlobeNewswire January 5, 2017

Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

GlobeNewswire December 14, 2016

Syndax Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 21, 2016